Literature DB >> 14557616

Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses.

Richard Singleton1, Nathalie Etchart, Sam Hou, Lisa Hyland.   

Abstract

Long-lasting protective antibody is not normally generated in children following primary respiratory syncytial virus (RSV) infection, frequently leading to reinfection. We used the BALB/c mouse model to examine the role of the nasal-associated lymphoid tissue and the bone marrow in the generation of RSV-specific long-lasting plasma cells, with a view to further understanding the mechanisms responsible for the poorly sustained RSV antibody levels following primary infection. We show here that substantial numbers of RSV-specific plasma cells were generated in the bone marrow following challenge, which were maintained thereafter. In contrast, in the nasal-associated lymphoid tissue, RSV-specific plasma cell numbers waned quickly both after primary infection and after challenge and were not maintained at a higher level after boosting. These data indicate that the inability to generate a robust local mucosal response in the nasal tissues may contribute substantially to the likelihood of subsequent reinfection and that the presence of serum anti-RSV antibody without local protection is not enough to protect against reinfection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557616      PMCID: PMC229280          DOI: 10.1128/jvi.77.21.11303-11311.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice.

Authors:  B Liang; L Hyland; S Hou
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

Authors:  R H Parrott; H W Kim; J O Arrobio; D S Hodes; B R Murphy; C D Brandt; E Camargo; R M Chanock
Journal:  Am J Epidemiol       Date:  1973-10       Impact factor: 4.897

3.  Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus.

Authors:  P L Ogra
Journal:  N Engl J Med       Date:  1971-01-14       Impact factor: 91.245

4.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness.

Authors:  J Mills; J E Van Kirk; P F Wright; R M Chanock
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

6.  Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection.

Authors:  K McIntosh; J McQuillin; P S Gardner
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

Review 7.  Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

Authors:  Jessie R Groothuis; Hiroshi Nishida
Journal:  Pediatr Int       Date:  2002-06       Impact factor: 1.524

8.  Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract.

Authors:  Jun Chang; Thomas J Braciale
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

9.  Synergistic upregulation of interleukin-8 secretion from pulmonary epithelial cells by direct and monocyte-dependent effects of respiratory syncytial virus infection.

Authors:  L H Thomas; M I Wickremasinghe; M Sharland; J S Friedland
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 10.  Respiratory syncytial virus infections in children.

Authors:  Mary Allen Staat
Journal:  Semin Respir Infect       Date:  2002-03
View more
  33 in total

1.  Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.

Authors:  Anna R Kwilas; Mark A Yednak; Liqun Zhang; Rachael Liesman; Peter L Collins; Raymond J Pickles; Mark E Peeples
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis.

Authors:  Julia Eckardt-Michel; Markus Lorek; Diane Baxmann; Thomas Grunwald; Günther M Keil; Gert Zimmer
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

3.  Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1.

Authors:  R Sealy; B G Jones; S L Surman; J L Hurwitz
Journal:  Vaccine       Date:  2010-08-01       Impact factor: 3.641

4.  Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut.

Authors:  Rajeev Rudraraju; Sherri Surman; Bart Jones; Robert Sealy; David L Woodland; Julia L Hurwitz
Journal:  Virology       Date:  2011-01-11       Impact factor: 3.616

Review 5.  Mucosal vaccines against respiratory syncytial virus.

Authors:  Kejian Yang; Steven M Varga
Journal:  Curr Opin Virol       Date:  2014-04-29       Impact factor: 7.090

6.  Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.

Authors:  Susan M Bueno; Pablo A González; Kelly M Cautivo; Jorge E Mora; Eduardo D Leiva; Hugo E Tobar; Glenn J Fennelly; Eliseo A Eugenin; William R Jacobs; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 7.  Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.

Authors:  Janyra A Espinoza; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

8.  Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.

Authors:  Teresa R Johnson; Christina N Johnson; Kizzmekia S Corbett; Gretchen C Edwards; Barney S Graham
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

9.  Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma.

Authors:  Nandini Krishnamoorthy; Anupriya Khare; Timothy B Oriss; Mahesh Raundhal; Christina Morse; Manohar Yarlagadda; Sally E Wenzel; Martin L Moore; R Stokes Peebles; Anuradha Ray; Prabir Ray
Journal:  Nat Med       Date:  2012-09-09       Impact factor: 53.440

10.  Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection.

Authors:  Jae-Rang Yu; Sol Kim; Jee-Boong Lee; Jun Chang
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.